6th Rijeka Forum on Neurodegenerative Diseases “Neurodegeneration updates and the 30 years of Amyloid Cascade Hypothesis”
September 25-28, 2022
This event is organised by the Clinic of Neurology UHC Rijeka together with the Croatian Academy of Sciences and Arts and… Continue Reading
The European Medicines Agency’s annual report for 2021 provides an overview of the Agency’s activities to protect and promote public (and animal) health in the European Union (EU) and highlights EMA’s most significant achievements.
Alzheimer Europe is proud to launch a special publication, to celebrate 10 years of the inspirational work of the European Working Group of People with Dementia (EWGPWD). Congratulations to the group on its 10th anniversary! The publication was launched by… Continue Reading
On 14 June 2022, Alzheimer Europe held its first in-person European Parliament Lunch Debate since February 2020, which focused on “Neurological conditions and mental health in EU and WHO Europe programmes”.
The new EAN President-Elect highlights some hopes and objectives for the future of the EAN, including updates on the work of the Covid-19 Task Force and the Coordinating Panel on Diversity, Equity and Inclusion in Neurology.
Our research paper of the month presents the results of the ‘SWIFT direct’ trial, a randomised, open-label, blinded-outcome trial, aiming to investigate whether thrombectomy alone would be non-inferior to thrombectomy plus intravenous alteplase in patients with acute ischaemic stroke due to anterior circulation large vessel occlusion.
With relatively few chances for EAN staff and members to meet in person, we decided to use this platform to present the team behind the scenes. This time it's Patrycja, our Acting Head of Membership, and Martin from the Office/IT Department.